Dipeptide Peptidase 4 Inhibitors Global Market Report 2024

The dipeptide peptidase 4 inhibitors market size has grown strongly in recent years. It will grow from $10.73 billion in 2023 to $11.3 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to several factors including improved access to diabetes treatments, expanding indications for DPP-4 inhibitors beyond type 2 diabetes, increased utilization of DPP-4 inhibitors in triple therapy regimens, a growing geriatric population, heightened focus on healthcare, greater emphasis on disease prevention, rising usage of oral anti-diabetic drugs, and increased adoption in primary care settings.

The dipeptide peptidase 4 inhibitors market size is expected to see strong growth in the next few years. It will grow to $13.93 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to several factors including the increasing prevalence of type 2 diabetes, growing demand for effective diabetes management, a rising aging population contributing to diabetes incidence, increasing focus on personalized medicine, growing adoption of DPP-4 inhibitors in emerging markets, rising prevalence of diabetes and related complications, and increasing demand for diabetes management solutions. Major trends expected in this period include collaborations among stakeholders, product approvals, and ongoing research and development efforts aimed at improving diabetes treatment options.

The growth of the dipeptidyl peptidase 4 inhibitors market is expected to be driven by the rising prevalence of diabetes. Diabetes, a chronic medical condition affecting glucose metabolism, is on the rise due to widespread adoption of sedentary lifestyles and unhealthy eating habits. Dipeptidyl peptidase 4 inhibitors play a key role in diabetes management by enhancing glycemic control through inhibition of incretin hormone degradation. For example, the International Diabetes Federation reported that in 2.02 trillion adults (1 in 10) were living with diabetes, a number expected to increase to 643 million by 2030 and 783 million by 2045. Thus, the increasing prevalence of diabetes fuels the dipeptidyl peptidase 4 inhibitors market.

Government initiatives for diabetes management are also expected to contribute to the growth of the dipeptidyl peptidase 4 inhibitors market. These initiatives, which include programs, policies, or actions undertaken by government entities at various levels, aim to address economic burden, health equity, and health management concerns related to diabetes. Government initiatives significantly impact the development of dipeptidyl peptidase 4 inhibitors by promoting health facilities, ensuring access, fostering innovation, and investing in drug development. For instance, the Australian National Diabetes Strategy 2021-2030, initiated by the Australian Government Department of Health in 2023, emphasizes prevention, detection, and management of diabetes, aligning with international policies such as the Global Action Plan for the Prevention and Control of Non-Communicable Diseases and the WHO Global Diabetes Compact. Therefore, rising government initiatives for diabetes management drive the dipeptidyl peptidase inhibitors market.

In August 2023, Lupin, an India-based pharmaceutical company, acquired two diabetes brands, ONDERO and ONDERO MET, from Boehringer Ingelheim International GmbH for an undisclosed amount. This acquisition aims to strengthen Lupin's commitment to providing superior treatment options for diabetes patients and expand its portfolio in the anti-diabetes segment. Boehringer Ingelheim International GmbH, a Germany-based company, manufactures dipeptidyl peptidase 4 (DPP-4) inhibitors.

Major companies operating in the dipeptide peptidase 4 inhibitors market are Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Macleods Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corp., Dr. Reddy's Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Biocon Limited, LG Life Sciences, USV Private Limited, Sanwa Kagaku Kenkyusho Co. Ltd., Kowa Company Ltd.

Asia-Pacific was the largest region in the dipeptide peptidase 4 inhibitors market in 2023. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dipeptide peptidase 4 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dipeptide peptidase 4 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of drugs utilized in the treatment of type 2 diabetes by augmenting active incretin levels to regulate blood sugar. DPP-4 inhibitors function by enhancing the action of incretin hormones, which stimulate insulin release and suppress glucagon release, thus reducing blood sugar levels.

The primary DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin, and others. Sitagliptin, for instance, is a medication belonging to the DPP-4 inhibitor class, used for managing type 2 diabetes by controlling blood sugar levels. It is available through various channels such as hospital pharmacies, retail pharmacies, and online platforms, and is prescribed for conditions such as type 2 diabetes, gestational diabetes, metabolic syndrome, among others.

The dipeptide peptidase 4 inhibitors market research report is one of a series of new reports that provides dipeptide peptidase 4 inhibitors market statistics, including dipeptide peptidase 4 inhibitors industry global market size, regional shares, competitors with a dipeptide peptidase 4 inhibitors market share, detailed dipeptide peptidase 4 inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the dipeptide peptidase 4 inhibitors industry. This dipeptide peptidase 4 inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dipeptidyl peptidase-4 inhibitors market consists of sales of gemigliptin, anagliptin, teneligliptin and trelagliptin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.